26 November 2024 false No description of principal activity Taxfiler 2024.6 16102229 business:PrivateLimitedCompanyLtd 2024-11-26 2025-11-30 16102229 2024-11-25 16102229 2024-11-26 2025-11-30 16102229 business:AuditExempt-NoAccountantsReport 2024-11-26 2025-11-30 16102229 business:FilletedAccounts 2024-11-26 2025-11-30 16102229 2025-11-30 16102229 business:Director1 2024-11-26 2025-11-30 16102229 business:RegisteredOffice 2024-11-26 2025-11-30 16102229 core:WithinOneYear 2025-11-30 16102229 core:AfterOneYear 2025-11-30 16102229 core:ShareCapital core:PreviouslyStatedAmount 2025-11-30 16102229 core:RetainedEarningsAccumulatedLosses core:PreviouslyStatedAmount 2025-11-30 16102229 core:PreviouslyStatedAmount 2025-11-30 16102229 business:SmallEntities 2024-11-26 2025-11-30 16102229 countries:EnglandWales 2024-11-26 2025-11-30 16102229 core:MotorVehicles 2024-11-26 2025-11-30 16102229 core:ComputerEquipment 2024-11-26 2025-11-30 16102229 core:MotorVehicles 2024-11-25 16102229 core:ComputerEquipment 2024-11-25 16102229 core:MotorVehicles 2025-11-30 16102229 core:ComputerEquipment 2025-11-30 iso4217:GBP xbrli:pure
Company Registration No. 16102229 (England and Wales)
Desire Meds Limited Unaudited accounts for the period from 26 November 2024 to 30 November 2025
Desire Meds Limited Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
Desire Meds Limited Company Information for the period from 26 November 2024 to 30 November 2025
Director
Oluwaseyi Opeyemi Ajala
Company Number
16102229 (England and Wales)
Registered Office
75 Riverside Lane Doncaster South Yorkshire DN2 4FF England
Accountants
Abacus Accounting Solutions Ltd 5 Pasture Close North Wembley Middlesex HA0 3JE
- 3 -
Desire Meds Limited Statement of financial position as at 30 November 2025
2025
Notes
£
Fixed assets
Tangible assets
4
17,289
Current assets
Debtors
5
750
Cash at bank and in hand
3,704
4,454
Creditors: amounts falling due within one year
6
(6,349)
Net current liabilities
(1,895)
Total assets less current liabilities
15,394
Creditors: amounts falling due after more than one year
7
(15,199)
Net assets
195
Capital and reserves
Called up share capital
100
Profit and loss account
95
Shareholders' funds
195
For the period ending 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 15 August 2026 and were signed on its behalf by
Oluwaseyi Opeyemi Ajala Director Company Registration No. 16102229
- 4 -
Desire Meds Limited Notes to the Accounts for the period from 26 November 2024 to 30 November 2025
1
Statutory information
Desire Meds Limited is a private company, limited by shares, registered in England and Wales, registration number 16102229. The registered office is 75 Riverside Lane, Doncaster, South Yorkshire, DN2 4FF, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Motor vehicles
25% reducing balance
Computer equipment
25% reducing balance
4
Tangible fixed assets
Motor vehicles
Computer equipment
Total
£
£
£
Cost or valuation
At cost
At cost
At 26 November 2024
-
-
-
Additions
22,500
552
23,052
At 30 November 2025
22,500
552
23,052
Depreciation
Charge for the period
5,625
138
5,763
At 30 November 2025
5,625
138
5,763
Net book value
At 30 November 2025
16,875
414
17,289
5
Debtors
2025
£
Amounts falling due within one year
Accrued income and prepayments
750
- 5 -
Desire Meds Limited Notes to the Accounts for the period from 26 November 2024 to 30 November 2025
6
Creditors: amounts falling due within one year
2025
£
Obligations under finance leases and hire purchase contracts
2,711
Taxes and social security
3,135
Other creditors
3
Accruals
500
6,349
7
Creditors: amounts falling due after more than one year
2025
£
Obligations under finance leases and hire purchase contracts
15,199
8
Average number of employees
During the period the average number of employees was 0.
- 6 -